Observational Study of Primary Mitochondrial Disease (SPIMM-300)

  • Research type

    Research Study

  • Full title

    A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)

  • IRAS ID

    218005

  • Contact name

    Grainne Gorman

  • Contact email

    grainne.gorman@newcastle.ac.uk

  • Sponsor organisation

    STEALTH BIOTHERAPEUTICS

  • Clinicaltrials.gov Identifier

    NCT03048617

  • Duration of Study in the UK

    0 years, 11 months, 31 days

  • Research summary

    This is a prospective, observational research study of the usual care for primary mitochondrial disease (PMD). There are no study treatments. PMD causes a varied group of disorders but a majority of patients with PMD suffer from signs and symptoms of muscle disease, exercise intolerance and fatigue, which frequently impact the patient’s ability to perform normal activities of daily life.

    The main purpose of this study is to look at the relationship between patients’ genetic test results and the signs and symptoms of PMD. Learning more about how variation in genes may relate to PMD symptoms may help in developing future treatments for PMD. Regional differences in the genetic test methods and in the standard clinical care of PMD patients will also be examined. In addition, the Sponsor will be looking at patient information in order to identify potential patients for future research studies of investigational drugs to treat PMD. Data will be collected from: (1) Investigator completed questionnaires that capture information from the patient’s medical record, (2) patient completed questionnaires about disease symptoms (unvalidated) and quality of life, and (3) a timed walking test to examine the extent of exercise tolerance and fatigue, an up-and-go test to assess mobility, and a sitto-stand test to assess functional lower limb strength and balance. The enrolment visit is the only required study visit. After this visit, information will be collected from routine clinic visits, or the study doctor will phone the study patients about every 6 months for up to a year.

  • REC name

    North East - Tyne & Wear South Research Ethics Committee

  • REC reference

    17/NE/0201

  • Date of REC Opinion

    15 Aug 2017

  • REC opinion

    Further Information Favourable Opinion